老年1型糖尿病伴低血糖患者中结合老年医学原则的持续葡萄糖监测:一项随机对照试验
研究纳入131例≥65岁1型糖尿病伴低血糖患者,随机分为结合老年医学原则的持续葡萄糖监测(CGM)干预组与常规内分泌科诊疗对照组,随访6个月。干预组血糖<70 mg/dL时间较基线的中位变化为-2.6%,对照组为-0.3%,中位差-2.3%(95%CI -3.7%, -1.3%;P<0.001),糖化血红蛋白两组无差异(7.5% vs 7.3%),干预具有成本效益(增量成本效果比每质量调整生命年71,623美元)。
要点
- 老年1型糖尿病伴低血糖患者中,结合老年医学原则的CGM干预6个月可降低血糖<70 mg/dL时间。
- 干预组低血糖时间中位变化-2.6%,对照组-0.3%,中位差-2.3%(95%CI -3.7%, -1.3%;P<0.001)。
- 糖化血红蛋白干预组7.5% vs 对照组7.3%,两组无差异;增量成本效果比为每质量调整生命年71,623美元。
核心结论
- 在老年1型糖尿病伴高低血糖风险患者中,结合老年医学原则的CGM使用可降低低血糖且不恶化血糖控制,并具有成本效益。
研究设计与样本
- 随机对照试验,纳入≥65岁1型糖尿病伴低血糖(2周内至少2次血糖<70 mg/dL持续≥20分钟)患者131例,随机分为干预组68例(CGM使用者33例)和对照组63例(CGM使用者40例),干预6个月。
主要发现
- 干预组低血糖时间从基线至6个月的中位变化为-2.6%,对照组为-0.3%,中位差-2.3%(95%CI -3.7%, -1.3%;P<0.001)。
- CGM初治者低血糖改善-2.8%(95%CI -5.6%, -0.8%),CGM使用者改善-1.2%(95%CI -2.7%, -0.1%)。
- 糖化血红蛋白干预组7.5% vs 对照组7.3%,两组无差异。
- 干预具有成本效益,增量成本效果比为每质量调整生命年71,623美元。
临床怎么用
- 作者认为,在老年1型糖尿病伴高低血糖风险患者中,结合老年医学原则的CGM使用可降低低血糖且不恶化血糖控制,并具有成本效益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Continuous glucose monitoring (CGM) use in older adults with type 1 diabetes (T1D) has shown benefits. However, the impact of CGM use, coupled with simplified treatment regimens and personalized glycemic goals that are better suited for older patients with multiple comorbidities and hypoglycemia, is not known. RESEARCH DESIGN AND METHODS: Older adults (≥65 years) with T1D with hypoglycemia (two or more episodes of hypoglycemia [blood glucose <70 mg/dL for ≥20 min over 2 weeks]) who were CGM naive or CGM users were randomized to intervention and control groups. The intervention consisted of the combined use of CGM with geriatric principles (i.e., adjusting goals based on overall health, and simplification of regimens based on CGM patterns and clinical characteristics) over 6 months. The control group received usual care by their endocrinologist. The primary end point was change in time when blood glucose was <70 mg/dL from baseline to 6 months. Cost-effectiveness was calculated using a health care sector perspective. RESULTS: We randomized 131 participants (aged 71 ± 5 years; 21% ≥75 years old) to the intervention (n = 68; CGM users = 33) or the control (n = 63; CGM users = 40) group. The median change in hypoglycemia from baseline to 6 months was -2.6% in the intervention group and -0.3% in the control group (median difference, -2.3% [95% CI -3.7%, -1.3%]; P < 0.001). This improvement was seen in both CGM naive (-2.8%; 95% CI -5.6%, -0.8%) and CGM users (-1.2%; 95% CI -2.7%, -0.1%). The HbA1c did not differ between the groups (7.5% vs. 7.3%). The intervention was cost-effective (incremental cost-effectiveness ratio $71,623 per quality adjusted life-year). CONCLUSIONS: In older adults with T1D and high risk of hypoglycemia, CGM use enhanced by geriatric principles can lower hypoglycemia without worsening glycemic control in a cost-effective fashion.
引用
- Munshi MN, Slyne C, Adam A, et al. Continuous Glucose Monitoring With Geriatric Principles in Older Adults With Type 1 Diabetes and Hypoglycemia: A Randomized Controlled Trial. Diabetes Care. 2025. PMID: 39325586. doi:10.2337/dc24-1069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。